10
Apr

Three days after Bristol-Myers Squibb filed for FDA approval of the NS5A drug daclatasvir combined with asunaprevir, an NS3 protease inhibitor, the biotech company has turned over some of the Phase III cards it will be playing for an approval in markets around the world.

…read more

Source: Bristol-Myers jockeys for promising position in hep C drug race

    

0 No comments